BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31285082)

  • 1. Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer.
    Suzuki K; Nagao S; Shibutani T; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
    Gynecol Oncol; 2019 Sep; 154(3):554-557. PubMed ID: 31285082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
    Redondo A; Colombo N; McCormack M; Dreosti L; Nogueira-Rodrigues A; Scambia G; Lorusso D; Joly F; Schenker M; Ruff P; Estevez-Diz M; Irahara N; Donica M; Gonzalez-Martín A
    Gynecol Oncol; 2020 Oct; 159(1):142-149. PubMed ID: 32763109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
    Ishikawa M; Shibata T; Iwata T; Nishio S; Takada T; Suzuki S; Horie K; Kudaka W; Kagabu M; Tanikawa M; Kitagawa R; Takekuma M; Kobayashi H; Yaegashi N;
    Gynecol Oncol; 2021 Aug; 162(2):292-298. PubMed ID: 34016453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.
    Downs LS; Judson PL; Argenta PA; Carson LF; Boente MP
    Gynecol Oncol; 2004 Nov; 95(2):347-51. PubMed ID: 15491756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
    Tinker AV; Fiorino L; O'Dwyer H; Kumar A
    Int J Gynecol Cancer; 2018 Oct; 28(8):1592-1599. PubMed ID: 30247250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
    Saloustros E; Nikolaou M; Kalbakis K; Polyzos A; Christofillakis C; Kentepozidis N; Pistamaltzian N; Kourousis C; Vamvakas L; Georgoulias V; Mavroudis D
    Clin Breast Cancer; 2018 Feb; 18(1):88-94. PubMed ID: 29153775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).
    Simpkins F; Drake R; Escobar PF; Nutter B; Rasool N; Rose PG
    Gynecol Oncol; 2015 Feb; 136(2):240-5. PubMed ID: 25485782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.
    Pectasides D; Fountzilas G; Papaxoinis G; Pectasides E; Xiros N; Sykiotis C; Koumarianou A; Psyrri A; Panayiotides J; Economopoulos T
    Int J Gynecol Cancer; 2009 May; 19(4):777-81. PubMed ID: 19509587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.
    Kitagawa R; Katsumata N; Ando M; Shimizu C; Fujiwara Y; Yoshikawa H; Satoh T; Nakanishi T; Ushijima K; Kamura T
    Gynecol Oncol; 2012 May; 125(2):307-11. PubMed ID: 22333993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
    Miura S; Maemondo M; Iwashima A; Harada T; Sugawara S; Kobayashi K; Inoue A; Nakagawa T; Takiguchi Y; Watanabe H; Ishida T; Terada M; Kagamu H; Gemma A; Yoshizawa H
    Invest New Drugs; 2017 Apr; 35(2):227-234. PubMed ID: 28150074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
    Lorusso D; Ferrandina G; Colombo N; Pignata S; Pietragalla A; Sonetto C; Pisano C; Lapresa MT; Savarese A; Tagliaferri P; Lombardi D; Cinieri S; Breda E; Sabatucci I; Sabbatini R; Conte C; Cecere SC; Maltese G; Scambia G
    Gynecol Oncol; 2019 Dec; 155(3):406-412. PubMed ID: 31677820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.
    Engel-Riedel W; Lowe J; Mattson P; Richard Trout J; Huhn RD; Gargano M; Patchen ML; Walsh R; Trinh MM; Dupuis M; Schneller F
    J Immunother Cancer; 2018 Feb; 6(1):16. PubMed ID: 29486797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
    Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
    Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer.
    Song D; Kong W; Zhang T; Han C; Liu T; Jiao S; Chen J
    J Obstet Gynaecol; 2019 Apr; 39(3):389-394. PubMed ID: 30663464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.
    Tinker AV; Bhagat K; Swenerton KD; Hoskins PJ
    Gynecol Oncol; 2005 Jul; 98(1):54-8. PubMed ID: 15904950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
    Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
    Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix.
    Sit AS; Kelley JL; Gallion HH; Kunschner AJ; Edwards RP
    Cancer Invest; 2004; 22(3):368-73. PubMed ID: 15493357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer.
    Takekida S; Fujiwara K; Nagao S; Yamaguchi S; Yoshida N; Kitada F; Kigawa J; Terakawa N; Nishimura R
    Int J Gynecol Cancer; 2010 Dec; 20(9):1563-8. PubMed ID: 21370599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.